 | Up a level |
Lebrun-Frénay, Christine; Siva, Aksel; Sormani, Maria Pia; Landes-Chateau, Cassandre; Mondot, Lydiane; Bovis, Francesca; Vermersch, Patrick; Papeix, Caroline; Thouvenot, Eric; Labauge, Pierre; Durand-Dubief, Françoise; Efendi, Husnu; Le Page, Emmanuelle; Terzi, Murat; Derache, Nathalie; Bourre, Bertrand; Hoepner, Robert; Karabudak, Rana; De Seze, Jérôme; Ciron, Jonathan; ... (2023). Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial. JAMA neurology, 80(10), pp. 1080-1088. American Medical Association 10.1001/jamaneurol.2023.2815
Hauser, Stephen L; Kappos, Ludwig; Bar-Or, Amit; Wiendl, Heinz; Paling, David; Williams, Mitzi; Gold, Ralf; Chan, Andrew; Milo, Ron; Das Gupta, Ayan; Karlsson, Goeril; Sullivan, Roseanne; Graham, Gordon; Merschhemke, Martin; Häring, Dieter A; Vermersch, Patrick (2023). The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment. Neurology and therapy, 12(5), pp. 1491-1515. Springer 10.1007/s40120-023-00518-0
Wiendl, Heinz; Schmierer, Klaus; Hodgkinson, Suzanne; Derfuss, Tobias; Chan, Andrew; Sellebjerg, Finn; Achiron, Anat; Montalban, Xavier; Prat, Alexandre; De Stefano, Nicola; Barkhof, Frederik; Leocani, Letizia; Vermersch, Patrick; Chudecka, Anita; Mwape, Claire; Holmberg, Kristina H; Boschert, Ursula; Roy, Sanjeev (2023). Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy. Neurology: Neuroimmunology and Neuroinflammation, 10(1) Wolters Kluwer Health 10.1212/NXI.0000000000200048
Gold, Ralf; Piani-Meier, Daniela; Kappos, Ludwig; Bar-Or, Amit; Vermersch, Patrick; Giovannoni, Gavin; Fox, Robert J; Arnold, Douglas L; Benedict, Ralph H B; Penner, Iris-Katharina; Rouyrre, Nicolas; Kilaru, Ajay; Karlsson, Göril; Ritter, Shannon; Dahlke, Frank; Hach, Thomas; Cree, Bruce A C (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of neurology, 269(9), pp. 5093-5104. Springer 10.1007/s00415-022-11166-z
de Stefano, Nicola; Barkhof, Frederik; Montalban, Xavier; Achiron, Anat; Derfuss, Tobias; Chan, Andrew; Hodgkinson, Suzanne; Prat, Alexandre; Leocani, Letizia; Schmierer, Klaus; Sellebjerg, Finn; Vermersch, Patrick; Wiendl, Heinz; Keller, Birgit; Roy, Sanjeev (2022). Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS. Neurology: neuroimmunology & neuroinflammation, 9(4), e1187. Wolters Kluwer Health 10.1212/NXI.0000000000001187
Coles, Alasdair J; Jones, Joanne L; Vermersch, Patrick; Traboulsee, Anthony; Bass, Ann D; Boster, Aaron; Chan, Andrew; Comi, Giancarlo; Fernández, Óscar; Giovannoni, Gavin; Kubala Havrdova, Eva; LaGanke, Christopher; Montalban, Xavier; Oreja-Guevara, Celia; Piehl, Fredrik; Wiendl, Heinz; Ziemssen, Tjalf (2022). Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Multiple sclerosis journal, 28(5), pp. 842-846. Sage 10.1177/13524585211061335
Pugliatti, Maura; Hartung, Hans-Peter; Oreja-Guevara, Celia; Pozzilli, Carlo; Airas, Laura; Alkhawajah, Mona; Grigoriadis, Nikolaos; Magyari, Melinda; Van Wijmeersch, Bart; Zakaria, Magd; Linker, Ralf; Chan, Andrew; Vermersch, Patrick; Berger, Thomas (2022). Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. Frontiers in immunology, 13, p. 1045101. Frontiers Research Foundation 10.3389/fimmu.2022.1045101
Hunter, Samuel F; Aburashed, Rany A; Alroughani, Raed; Chan, Andrew; Dive, Dominique; Eichau, Sara; Kantor, Daniel; Kim, Ho Jin; Lycke, Jan; Macdonell, Richard A L; Pozzilli, Carlo; Scott, Thomas; Sharrack, Basil; Wiendl, Heinz; Chung, Luke; Daizadeh, Nadia; Baker, Darren P; Vermersch, Patrick (2021). Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. Neurology and therapy, 10(2), pp. 803-818. Springer 10.1007/s40120-021-00262-3
